The sale is the entire company and assets to Regeneron Pharmaceuticals.

NPR reported in this issue:

Regeneron Pharmaceuticals said last month it aimed to buy the company for $256 million. Regeneron said it would comply with 23andMe’s privacy policies and applicable law. It said it would process all customer personal data in accordance with the consents, privacy policies and statements, terms of service, and notices currently in effect and have security controls in place designed to protect such data.

I don’t know much about Regeneron Pharmaceuticals but previously I read from others here that they represent the best case scenario.